Upgrade your membership to see all of the expert analysis we have published on NVO now!
Violation of 50-Day Moving Average Line Raised Concerns - Wednesday, July 24, 2024
Novo Nordisk (NVO -$1.68 or -1.26% to $131.60) abruptly slumped below its 50-day moving average (DMA) line ($138.56) with heavier volume behind damaging losses last week raising concerns and triggering a technical sell signal. Only a prompt rebound above the 50 DMA line would help its outlook improve. Fundamentals remain strong.
NVO was highlighted in the 6/07/24 mid-day report (read here) with pivot point cited based on its 3/07/24 high plus 10 cents. It was last shown in detail in this FSU section on 7/01/24 with an annotated graph under the headline, "Perched Near All-Time High Following Recent Gap Up With Volume".
NVO reported Mar '24 quarterly earnings +28% on +22% sales revenues versus the year-ago period, its 5th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 97 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 583 in Jun '24, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.4 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of C and an Accumulation/Distribution Rating of E.
Perched Near All-Time High Following Recent Gap Up With Volume - Monday, July 1, 2024
Novo Nordisk (NVO +$2.68 or +1.88% to $145.42) posted a gain today with higher (near average) volume, consolidating above its "max buy" level. Fundamentals remain strong. Prior highs in the $138 area define initial support to watch on pullbacks.
NVO was highlighted in the 6/07/24 mid-day report (read here) with pivot point cited based on its 3/07/24 high plus 10 cents. It was last shown in detail in this FSU section on 6/07/24 with an annotated graph under the headline, "Wedging Into New High Ground".
NVO reported Mar '24 quarterly earnings +28% on +22% sales revenues versus the year-ago period, its 5th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 97 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 569 in Mar '24, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.8 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of B and an Accumulation/Distribution Rating of B+.
Wedging Into New High Ground - Friday, June 7, 2024
Novo Nordisk (NVO +$0.48 or +0.34% to $142.88) was highlighted in yellow in the earlier mid-day report with pivot point cited based on its 3/07/24 high. It has been wedging higher without great volume behind a streak of 7 consecutive gains. To clinch a proper technical buy signal gains above the pivot point must be backed by at least +40% above-average volume. Fundamentals remain strong. It showed resilience since dropped from the Featured Stocks list on 5/02/24.
NVO was highlighted in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 4/24/24 with an annotated graph under the headline, "Fell Below 50-Day Moving Average Which May Act as Resistance".
NVO reported Mar '24 quarterly earnings +28% on +22% sales revenues versus the year-ago period, its 5th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 97 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 562 in Mar '24, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.4 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of C and an Accumulation/Distribution Rating of A.
Chart courtesy of www.stockcharts.com
Fell Below 50-Day Moving Average Which May Act as Resistance - Wednesday, April 24, 2024
Novo Nordisk (NVO -$2.48 or -1.93% to $126.16) pulled back and closed just below its 50-day moving average (DMA) line ($126.55) which may now act as resistance. The next near-term support to watch is prior lows in the $118 area. Its color code was changed to yellow while testing near the pivot point of the previously noted "3-weeks tight" base.
NVO was highlighted in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 4/03/24 with an annotated graph under the headline, "Volume Cools While Consolidating Above 50-Day Moving Average Line".
Keep in mind that this Denmark-based Medical - Ethical Drugs firm is due to report Mar '24 quarterly results on 5/02/24. Volume and volatility often increase near earnings news. NVO reported Dec '23 quarterly earnings +68% on +41% sales revenues versus the year-ago period, its 4th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 98 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 532 in Mar '24, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 0.8 is an unbiased indication its shares have been under distributional pressure over the past 50 days. It has a Timeliness Rating of B and an Accumulation/Distribution Rating of B+.
Chart courtesy of www.stockcharts.com
| Symbol/Exchange Company Name Industry Group | PRICE | CHANGE | Day High | Volume (% DAV) (% 50 day avg vol) | 52 Wk Hi | Featured Date | Price Featured | Pivot Featured |
| Max Buy | ||||||||
 NVO - NYSENovo Nordisk ADR Medical-Ethical Drugs | $126.16 | -2.48 -1.93% | $127.32 | 3,092,009 50 DAV is 4,792,000 | $138.28 -8.76% | 3/1/2024 | $124.23 | PP = $124.97 |
| MB = $131.22 | ||||||||
 Most Recent Note - 4/24/2024 5:13:30 PMG - Slumped below its 50 DMA line ($126) which may now act as resistance. A rebound above the 50 DMA line is needed for its outlook to improve. See the latest FSU analysis for more details and a new annotated graph. >>> FEATURED STOCK ARTICLE : Fell Below 50-Day Moving Average Which May Act as Resistance - 4/24/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| AXON - NASDAQ Axon Enterprise Security/Sfty | $302.41 | +0.85 0.28% | $308.12 | 492,314 50 DAV is 528,000 | $329.87 -8.32% | 4/5/2024 | $309.90 | PP = $325.73 |
| MB = $342.02 | ||||||||
| Most Recent Note - 4/23/2024 5:59:01 PM Y - Posted a gain today with near-average volume and closed just above its 50 DMA line ($301). Color code was changed to yellow with new pivot point cited based on its 3/04/24 high plus 10 cents. A gain above the pivot point backed by at least +40% above average volume is needed to trigger a proper technical buy signal. Fundamentals remain strong. >>> FEATURED STOCK ARTICLE : Volume Totals Cooling While Building a New Base - 4/8/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| TDG - NYSE TransDigm Group Aerospace/Defense | $1,241.62 | -0.78 -0.06% | $1,255.59 | 218,686 50 DAV is 196,000 | $1,248.39 -0.54% | 4/12/2024 | $1,224.21 | PP = $1,246.32 |
| MB = $1,308.64 | ||||||||
| Most Recent Note - 4/23/2024 5:54:37 PM Y - Posted a solid gain today with +22% above average volume for a best-ever close. Color code was changed to yellow after holding its ground in a tight range near its all-time high. New pivot point was cited based on its 4/04/24 high plus 10 cents. Subsequent gains above the pivot point backed by at least +40% above average volume are needed to trigger a proper new technical buy signal. Its 50 DMA line ($1,193) defines near-term support to watch. >>> FEATURED STOCK ARTICLE : Volume Totals Cooling While Perched Near High - 4/9/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| PCAR - NASDAQ Paccar Trucks and Parts-Hvy Duty | $113.74 | +0.42 0.37% | $114.83 | 2,597,639 50 DAV is 2,262,000 | $125.50 -9.37% | 1/23/2024 | $100.35 | PP = $98.57 |
| MB = $103.50 | ||||||||
| Most Recent Note - 4/24/2024 5:17:09 PM G - Halted its slide after a recently noted slump below its 50 DMA line ($116) triggered a technical sell signal. A prompt rebound above the 50 DMA line is needed for its outlook to improve. Fundamentals remain strong. >>> FEATURED STOCK ARTICLE : Pulling Back From High and Slumping Toward 50-Day Moving Average - 4/12/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| HUBB - NYSE Hubbell Electrical-Power/Equipmt | $398.55 | +0.55 0.14% | $408.00 | 335,232 50 DAV is 402,000 | $429.61 -7.23% | 1/30/2024 | $343.26 | PP = $336.83 |
| MB = $353.67 | ||||||||
| Most Recent Note - 4/24/2024 5:15:39 PM G - Posted a 3rd consecutive gain today with below-average volume after finding prompt support near its 50 DMA line ($392.82). >>> FEATURED STOCK ARTICLE : Closed Just Below 50-Day Moving Average With Quiet Loss - 4/19/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| Symbol/Exchange Company Name Industry Group | PRICE | CHANGE | Day High | Volume (% DAV) (% 50 day avg vol) | 52 Wk Hi | Featured Date | Price Featured | Pivot Featured |
| Max Buy | ||||||||
| USLM - NASDAQ U.S. Lime & Minerals Bldg-Cement/Concrt/Ag | $304.00 | -0.28 -0.09% | $305.50 | 18,369 50 DAV is 23,000 | $308.00 -1.30% | 2/9/2024 | $254.68 | PP = $265.09 |
| MB = $278.34 | ||||||||
| Most Recent Note - 4/23/2024 6:01:02 PM G - Posted a 3rd consecutive gain today challenging its all-time high. Its 50 DMA line ($282.71) defines near-term support to watch. >>> FEATURED STOCK ARTICLE : Gain With Light Volume for Best Ever Close - 4/5/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| PAY - NYSE Paymentus Holdings Finance-CrdtCard/PmtPr | $20.62 | +0.44 2.18% | $20.66 | 331,108 50 DAV is 395,000 | $25.21 -18.21% | 3/5/2024 | $19.97 | PP = $18.89 |
| MB = $19.83 | ||||||||
| Most Recent Note - 4/24/2024 5:18:52 PM G - Posted a 3rd consecutive gain today with ever-increasing (but below-average) volume, finding support near its 50 DMA line ($19.75). Prior highs in the $18 range define the next support. More damaging losses would raise greater concerns. >>> FEATURED STOCK ARTICLE : Prior Highs Define Important Near-Term Support - 4/22/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| HUBS - NYSE HubSpot Comp Sftwr-Spec Enterprs | $651.74 | -0.04 -0.01% | $664.02 | 399,494 50 DAV is 546,000 | $693.85 -6.07% | 4/4/2024 | $686.66 | PP = $660.10 |
| MB = $693.11 | ||||||||
| Most Recent Note - 4/23/2024 6:03:00 PM Y - Posted a solid gain today with +25% above average volume, finding support at its 50 DMA line ($626). Stalled after highlighted yellow in the 4/04/24 mid-day report with pivot point cited based on its 2/09/24 high plus 10 cents. Fundamentals remain strong. Faces some resistance due to old overhead supply up to the $866 level. >>> FEATURED STOCK ARTICLE : Encountered Distributional Pressure and Finished Below Pivot Point - 4/4/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
Volume Cools While Consolidating Above 50-Day Moving Average Line - Wednesday, April 3, 2024
Novo Nordisk (NVO +$0.69 or +0.55% to $127.15) halted its slide with a small gain today backed by light volume. It has been pulling back with recent losses backed by below-average volume. Its 50-day moving average (DMA) line ($123.08) defines near-term support above prior lows in the $118 area. Its color code was changed to yellow while testing near the pivot point of the previously noted "3-weeks tight" base.
NVO was highlighted in yellow in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 3/12/24 with an annotated graph under the headline, "Perched at All-Time High After Rallying from Advanced '3-Weeks Tight'".
This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. NVO reported Dec '23 quarterly earnings +68% on +41% sales revenues versus the year-ago period, its 4th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 98 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 527 in Dec '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.0 is an unbiased indication its shares have been neutral concerning accumulation/distribution over the past 50 days. It has a Timeliness Rating of B and an Accumulation/Distribution Rating of B+.
Perched at All-Time High After Rallying from Advanced "3-Weeks Tight" - Tuesday, March 12, 2024
Novo Nordisk (NVO +$3.87 or +2.95% to $135.11) posted a solid volume-driven gain today for its second-best ever close. After a recenlty noted "3-weeks tight" base it quickly powered well above its "max buy" level. Recent lows in the $118 area define initial support to watch above its 50-day moving average (DMA) line ($116) on any pullbacks.
NVO was highlighted in yellow in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 2/08/24 with an annotated graph under the headline, "Extended From Any Sound Base After Volume-Driven Gains".
This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. NVO reported Dec '23 quarterly earnings +68% on +41% sales revenues versus the year-ago period, its 4th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 98 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 507 in Dec '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under slight accumulation over the past 50 days. It has a Timeliness Rating of A and an Accumulation/Distribution Rating of B+.
Chart courtesy of www.stockcharts.com
| Symbol/Exchange Company Name Industry Group | PRICE | CHANGE | Day High | Volume (% DAV) (% 50 day avg vol) | 52 Wk Hi | Featured Date | Price Featured | Pivot Featured |
| Max Buy | ||||||||
| ANET - NYSE Arista Networks Computer-Networking | $281.86 | +10.84 4.00% | $281.95 | 2,281,603 50 DAV is 2,285,000 | $292.66 -3.69% | 10/31/2023 | $188.84 | PP = $198.80 |
| MB = $208.74 | ||||||||
| Most Recent Note - 3/12/2024 9:43:43 PM G - Posted a solid gain today after testing support at its 50 DMA line ($263.70) on the prior session. It has not formed a sound base of sufficient length. >>> FEATURED STOCK ARTICLE : Best Ever Close for Arista Networks - 3/1/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| NVO - NYSE Novo Nordisk ADR Medical-Ethical Drugs | $135.11 | +3.87 2.95% | $135.12 | 6,326,961 50 DAV is 5,311,000 | $138.28 -2.29% | 3/1/2024 | $124.23 | PP = $124.97 |
| MB = $131.22 | ||||||||
| Most Recent Note - 3/12/2024 9:35:46 PM G - Posted a solid gain today for its second-best ever close. Last week it rallied from a noted new advanced "3-weeks tight" base. Recent lows in the $118 area define initial support to watch above its 50 DMA line ($116). See the latest FSU analysis for more details and a new annotated graph. >>> FEATURED STOCK ARTICLE : Perched at All-Time High After Rallying from Advanced "3-Weeks Tight" - 3/12/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| AXON - NASDAQ Axon Enterprise Security/Sfty | $311.25 | +0.32 0.10% | $312.07 | 400,523 50 DAV is 464,000 | $325.63 -4.42% | 11/8/2023 | $127.84 | PP = $223.30 |
| MB = $234.47 | ||||||||
| Most Recent Note - 3/11/2024 11:02:52 PM G - Stubbornly holding its ground near its all-time high. Bullish action came after it reported Dec '23 quarterly earnings +60% on +29% sales revenues versus the year-ago period. Its 50-day moving average (DMA) line ($268) defines near-term support above the prior high ($262.95 on 1/12/24). >>> FEATURED STOCK ARTICLE : Reversal at All-Time High After 7 Consecutive Gains - 2/12/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| TDG - NYSE TransDigm Group Aerospace/Defense | $1,183.13 | +31.39 2.73% | $1,184.39 | 228,000 50 DAV is 221,000 | $1,207.58 -2.02% | 12/12/2023 | $1,000.39 | PP = $1,013.18 |
| MB = $1,063.84 | ||||||||
| Most Recent Note - 3/12/2024 9:07:11 PM G - Posted a solid gain today with average volume. Its 50 DMA line ($1,103) defines near-term support to watch. >>> FEATURED STOCK ARTICLE : Transdigm Perched Near All-Time High - 2/14/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| CRWD - NASDAQ CrowdStrike Holdings Computer Sftwr-Security | $329.22 | +11.85 3.73% | $333.81 | 4,151,393 50 DAV is 4,171,000 | $365.00 -9.80% | 1/2/2024 | $246.42 | PP = $261.91 |
| MB = $275.01 | ||||||||
| Most Recent Note - 3/12/2024 9:45:23 PM G - Perched within close striking distance of its all-time high, it has not formed a sound base of sufficient length. Its 50 DMA ($300) recently acted as support. Fundamentals remain strong after it reported Jan ''24 quarterly earnings +102% on +33% sales revenues versus the year-ago period. >>> FEATURED STOCK ARTICLE : Encountered Distributional Pressure After Spiking to New High - 3/11/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| Symbol/Exchange Company Name Industry Group | PRICE | CHANGE | Day High | Volume (% DAV) (% 50 day avg vol) | 52 Wk Hi | Featured Date | Price Featured | Pivot Featured |
| Max Buy | ||||||||
| ELF - NYSE e.l.f. Beauty Cosmetics/Personal Care | $205.31 | +11.33 5.84% | $206.57 | 1,179,598 50 DAV is 1,538,000 | $221.83 -7.45% | 1/2/2024 | $138.23 | PP = $153.63 |
| MB = $161.31 | ||||||||
| Most Recent Note - 3/12/2024 9:41:21 PM G - Extended from any sound base, it posted a big gain today with below-average volume. Its 50 DMA line ($171.65) defines important near-term support to watch. Fundamentals remain strong. >>> FEATURED STOCK ARTICLE : Encountering Distributional Pressure Near All-Time High - 3/8/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| KOF - NYSE Coca Cola Femsa Sab Ads FOOD and BEVERAGE - Beverages - Soft Drinks | $98.39 | +1.83 1.90% | $98.79 | 205,734 50 DAV is 168,700 | $104.38 -5.74% | 1/12/2024 | $93.38 | PP = $99.34 |
| MB = $104.31 | ||||||||
| Most Recent Note - 3/12/2024 9:37:21 PM Y - Posted a 2nd consecutive gain today with slightly above-average volume, finding support above its 50 DMA line ($95.23). There was a noted "negative reversal" on 2/20/24 at its all-time high. Reported Dec ''23 quarterly earnings -13% on +24% sales revenues versus the year-ago period, raising fundamental concerns. >>> FEATURED STOCK ARTICLE : Perched at High With Earnings News Due - 2/21/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| PCAR - NASDAQ Paccar Trucks and Parts-Hvy Duty | $114.78 | +0.75 0.66% | $115.26 | 1,764,532 50 DAV is 2,223,000 | $116.88 -1.80% | 1/23/2024 | $100.35 | PP = $98.57 |
| MB = $103.50 | ||||||||
| Most Recent Note - 3/8/2024 12:45:03 PM G - Extended from any sound base and holding its ground stubbornly at its all-time high after steadily wedging higher with gains lacking great volume conviction. Its 50 DMA line ($103) defines near-term support to watch on pullbacks. Fundamentals remain strong. >>> FEATURED STOCK ARTICLE : Extended From Any Sound Base After 7 Weekly Gains - 2/26/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| HUBB - NYSE Hubbell Electrical-Power/Equipmt | $396.93 | +9.50 2.45% | $397.32 | 540,640 50 DAV is 405,000 | $396.92 0.00% | 1/30/2024 | $343.26 | PP = $336.83 |
| MB = $353.67 | ||||||||
| Most Recent Note - 3/12/2024 9:01:56 PM G - Rallied for a new all-time high and closed at the session high with today''s volume-driven gain, getting more extended from the previously noted base. Its 50 DMA line ($350) defines important support to watch on pullbacks. >>> FEATURED STOCK ARTICLE : Inched to New Highs With Average Volume - 2/28/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| MANH - NASDAQ Manhattan Associates Computer Sftwr-Enterprse | $256.19 | +0.69 0.27% | $258.57 | 521,368 50 DAV is 354,000 | $266.94 -4.03% | 1/31/2024 | $240.57 | PP = $230.71 |
| MB = $242.25 | ||||||||
| Most Recent Note - 3/12/2024 9:47:13 PM G - Posted a small gain today with +47% above average volume. It is extended from the previously noted base. Its 50 DMA line ($234) defines near-term support to watch above prior highs in the $230 area. >>> FEATURED STOCK ARTICLE : Hovering Near All-Time High After Streak of Small Gains - 2/29/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| Symbol/Exchange Company Name Industry Group | PRICE | CHANGE | Day High | Volume (% DAV) (% 50 day avg vol) | 52 Wk Hi | Featured Date | Price Featured | Pivot Featured |
| Max Buy | ||||||||
| USLM - NASDAQ U.S. Lime & Minerals Bldg-Cement/Concrt/Ag | $292.05 | +3.73 1.29% | $294.98 | 17,533 50 DAV is 19,000 | $289.95 0.72% | 2/9/2024 | $254.68 | PP = $265.09 |
| MB = $278.34 | ||||||||
| Most Recent Note - 3/8/2024 12:31:38 PM G - Wedging to new all-time highs above its "max buy" level with recent gains lacking great volume conviction and its color code is changed to green. Recent gains above the pivot point were not backed by the minimum +40% above average volume necessary to trigger a proper technical buy signal. Through Dec '23 its quarterly and annual earnings (C and A criteria) history has been strong, a good match with the fact-based investment system's guidelines. Thinly traded firm has only 5.7 million shares outstanding (S criteria), which can contribute to greater price volatility in the event of institutional buying or selling. >>> FEATURED STOCK ARTICLE : Strong Finish for Thinly Traded U.S Lime & Minerals - 2/9/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| NOW - NYSE ServiceNow Computer Sftwr-Enterprse | $789.56 | +32.82 4.34% | $793.00 | 1,529,685 50 DAV is 1,229,000 | $815.32 -3.16% | 2/22/2024 | $771.75 | PP = $815.32 |
| MB = $856.09 | ||||||||
| Most Recent Note - 3/12/2024 9:39:47 PM Y - Posted a solid gap up gain today with above-average volume. Found prompt support near its 50 DMA line ($754) in recent weeks while consolidating, while recent lows define the next important near-term support to watch. >>> FEATURED STOCK ARTICLE : Found Support With a Solid Gap Up from 10-Week Moving Average - 2/23/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| SNPS - NASDAQ Synopsys Computer Sftwr-Design | $576.72 | +11.40 2.02% | $577.19 | 622,717 50 DAV is 1,360,000 | $629.38 -8.37% | 2/22/2024 | $600.65 | PP = $582.85 |
| MB = $611.99 | ||||||||
| Most Recent Note - 3/12/2024 9:06:25 PM Y - Posted a small gain today with below-average volume, and volume totals have been cooling in recent weeks while consolidating. The prior low ($555 on 3/11/24) defines near-term support above its 50 DMA line ($543.46). Previously noted - "A strong volume-driven gain and close above the pivot point is needed to clinch a proper technical buy signal. Reported Jan ''24 quarterly earnings +36% on +21% sales revenues versus the year-ago period, its 3rd strong quarter above the +25% minimum earnings guideline (C criteria). Annual earnings growth (A criteria) has been strong and steady." >>> FEATURED STOCK ARTICLE : Gapped Up for New High But Ended Near Session Low - 2/22/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
| PAY - NYSE Paymentus Holdings Finance-CrdtCard/PmtPr | $23.93 | +3.11 14.94% | $24.00 | 1,434,582 50 DAV is 220,000 | $21.07 13.57% | 3/5/2024 | $19.97 | PP = $18.89 |
| MB = $19.83 | ||||||||
| Most Recent Note - 3/12/2024 1:22:36 PM G - Spiking to new 52-week highs with today's 3rd consecutive volume-driven gain, getting extended from any sound base. Its color code was changed to green after rising above its "max buy" level. Prior highs in the $18 range define important initial support to watch on pullbacks. >>> FEATURED STOCK ARTICLE : Big Gap Up Gain Triggered Technical Buy Signal - 3/5/2024 | View all notes | Set NEW NOTE alert | Company Profile | SEC News | Chart | Request a new note | ||||||||
Extended From Any Sound Base After Volume-Driven Gains - Thursday, February 8, 2024
Novo Nordisk (NVO -$0.27 or -0.23% to $118.39) is stubbornly holding its ground and extended from any sound base after a recent spurt of volume-driven gains. Its 50-day moving average (DMA) line ($105) and recent low ($103.38 on 1/23/24) define important near-term support to watch on pullbacks.
NVO was highlighted in yellow in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 1/05/24 with an annotated graph under the headline, "Gap Up Gain on Prior Session Triggered Technical Buy Signal".
This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. NVO reported Dec '23 quarterly earnings +68% on +41% sales revenues versus the year-ago period, its 4th strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been strong and steady. It has a 98 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 478 in Dec '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under slight accumulation over the past 50 days. It has a Timeliness Rating of A and an Accumulation/Distribution Rating of B.
Gap Up Gain on Prior Session Triggered Technical Buy Signal - Friday, January 5, 2024
Novo Nordisk (NVO -$1.65 or -1.53% to $105.98) pulled back with average volume. On Thursday's session it gapped up and triggered a technical buy signal with a considerable gain backed by +118% above average volume. Prior highs in the $105 area defien initial support to watch above the 50-day moving average ($100.42).
NVO was highlighted in yellow in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. It was last shown in detail in this FSU section on 12/11/23 with an annotated graph under the headline, "Managed a 'Positive Reversal' but Still Below 50-Day Moving Average".
This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. NVO reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady. It has a 97 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 470 in Sep '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.1 is an unbiased indication its shares have been under slight accumulation over the past 50 days. It has a Timeliness Rating of B and an Accumulation/Distribution Rating of B.
Managed a "Positive Reversal" but Still Below 50-Day Moving Average - Monday, December 11, 2023
Novo Nordisk (NVO +$0.01 or +0.01% to $96.65) suffered a 5th consecutive loss with lackluster volume. It gapped down on 11/28/23 then steadily slumped below its 50-day moving average (DMA) line in recent weeks. A prompt rebound above the 50 DMA line is needed for its outlook to improve.
NVO was highlighted in yellow in the 11/02/23 mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. Disciplined investors will note that it did not produce the subsequent gains for new highs backed by at least +40% above average volume needed to trigger a technical buy signal. It wedged higher with gains lacking volume conviction.
This Denmark-based Medical - Ethical Drugs firm's shares split 2-1 on 9/20/23. NVO reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady. It has a 97 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 448 in Sep '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.3 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of B and an Accumulation/Distribution Rating of B.
Approaching Prior High With Strong Fundamentals - Thursday, November 2, 2023
Novo Nordisk (NVO +$3.25 or +3.33% to $100.93) was highlighted in yellow in the earlier mid-day report (read here) with pivot point cited based on its 10/13/23 high plus 10 cents while building on an advanced ascending base. Subsequent gains for new highs backed by at least +40% above averqage volume are needed to trigger a technical buy signal.
This Denmark-based Medical - Ethical Drugs firm gapped up today challenging its all-time high. It found support after briefly undercutting its 50-day moving average (DMA) line in recent weeks. Shares split 2-1 on 9/20/23.
NVO reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady. It has a 96 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
NVO reported Sep '23 quarterly earnings +69% on +39% sales revenues versus the year-ago period, its 3rd strong quarter well above the +25% minimum earnings guideline (C criteria). Annual earnings growth has been slow and steady. It has a 96 Earnings Per Share Rating, well above the 80+ minimum for buy candidates.
The number of top-rated funds owning its shares rose from 372 in Dec '22 to 455 in Sep '23, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.5 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of A and an Accumulation/Distribution Rating of B+.
